NCT00723931View on ClinicalTrials.gov

PegIntron Injection Surveillance Plan (Study P04123)

CompletedOBSERVATIONAL

Enrollment

1,267

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

November 30, 2009

Study Completion Date

November 30, 2009

Conditions

Hepatitis C, Chronic

Interventions

BIOLOGICAL

Peginterferon alfa-2b (SCH 54031)

Surveillance will be conducted after administration of peginterferon alfa-2b (administered according to the directions on the products' labeling). PegIntron Injection for surveillance is a weight-based dosing product administered at a dose of 0.5/1.0 ug/kg or 1.5 ug/kg. Administration of treatment is not part of this study.

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00723931 - PegIntron Injection Surveillance Plan (Study P04123) | Biotech Hunter | Biotech Hunter